Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Svane

Showing results (781-790 of 811) with videos related to

Pageof 82
Sort By:
Science (New York, N.Y.)|September 5, 2024
In vivo dendritic cell reprogramming for cancer immunotherapyErvin Ascic, Fritiof Åkerström, Malavika Sreekumar Nair, et al.
Frontiers in Immunology|March 31, 2023
First in man study: Bcl-Xl_42-CAF<sup>®</sup>09b vaccines in patients with locally advanced prostate cancerSofie Kirial Mørk, Per Kongsted, Marie Christine Wulff Westergaard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanomaY J L Jansen, E A Rozeman, R Mason, et al.
Iscience|November 13, 2023
Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapySasha A S Kjeldsen, Lise L Gluud, Mikkel P Werge, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
Cellular and Molecular Life Sciences : CMLS|March 25, 2022
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor typesNicholas Willumsen, Christina Jensen, George Green, et al.
JAMA Oncology|November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 TrialPaolo A Ascierto, Georgina V Long, Caroline Robert, et al.
Frontiers in Immunology|April 18, 2024
IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognitionAnnie Borch, Ibel Carri, Birkir Reynisson, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapySiri Amanda Tvingsholm, Marcus Svensson Frej, Vibeke Mindahl Rafa, et al.
The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
Pageof 82

Showing results (781-790 of 811) with videos related to

Sort By:
Pageof 82
Science (New York, N.Y.)|September 5, 2024
In vivo dendritic cell reprogramming for cancer immunotherapyErvin Ascic, Fritiof Åkerström, Malavika Sreekumar Nair, et al.
Frontiers in Immunology|March 31, 2023
First in man study: Bcl-Xl_42-CAF<sup>®</sup>09b vaccines in patients with locally advanced prostate cancerSofie Kirial Mørk, Per Kongsted, Marie Christine Wulff Westergaard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanomaY J L Jansen, E A Rozeman, R Mason, et al.
Iscience|November 13, 2023
Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapySasha A S Kjeldsen, Lise L Gluud, Mikkel P Werge, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
Cellular and Molecular Life Sciences : CMLS|March 25, 2022
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor typesNicholas Willumsen, Christina Jensen, George Green, et al.
JAMA Oncology|November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 TrialPaolo A Ascierto, Georgina V Long, Caroline Robert, et al.
Frontiers in Immunology|April 18, 2024
IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognitionAnnie Borch, Ibel Carri, Birkir Reynisson, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapySiri Amanda Tvingsholm, Marcus Svensson Frej, Vibeke Mindahl Rafa, et al.
The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
Pageof 82